

## *MolMed clinical development update: four studies accepted for presentation at ASCO 2013*

Milan (Italy), 16 May 2013 – MolMed S.p.A. (MLM.MI) today announced that four studies on its investigational therapeutics NGR-hTNF and TK have been accepted for presentation at the 49<sup>th</sup> ASCO Annual Meeting, that will take place in Chicago (IL, USA) from May 31<sup>st</sup> to June 4<sup>th</sup>, 2013. Abstracts are now available on the ASCO 2013 website (<http://chicago2013.asco.org>).

This year yet again MolMed had an important number of studies accepted for presentation at ASCO meeting, confirming the quality of our clinical development programme.

We are particularly pleased to communicate that the study on our cell therapy TK has been selected for an oral presentation in the section "Leukemia, Myelodysplasia, and Transplantation", reflecting the recognised potential of our strategy. In particular, results from an overall assessment on 128 patients with high-risk haematological malignancies who were treated with TK cells in 10 completed Phase I/II clinical trials in different countries will be presented. Long-term follow-up data confirm the clinical benefit and the safety of this cell therapy.

For NGR-hTNF, new data presented at ASCO will be mainly focused on the results of two randomised Phase II trials: in non-small cell lung cancer (NSCLC) and in soft tissue sarcoma (STS). Both these studies confirm the clinical benefit induced by the treatment, with a very favourable tolerability profile.

New data disclosed at ASCO will be announced in separate press releases during the meeting.

### *Presentation schedule at ASCO 2013*

Abstract #	Abstract title	Presentation date & time (CDT)
7007	Long-term safety and survival outcomes after TK-expressing donor lymphocyte infusion (TK-DLI) in allogeneic hematopoietic stem cell transplantation (HSCT).	Tuesday 4 June, 10:15 - 10:30 *
8035	Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non small cell lung cancer (NSCLC)	Sunday 2 June, 8:00 - 12:00 **
10568	Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS)	Saturday 1 June, 13:15 - 17:00 **
3038	Relationships of peripheral blood lymphocyte counts (PBLC) with antitumor activity of NGR-hTNF given in combination with chemotherapy (CT)	Monday 3 June, 8:00 - 11:45 **

\* Oral presentation    \*\* Poster

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

### *About MolMed*

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development:

#### **FROM GENES TO THERAPY**

#### **MOLMED S.p.A.**

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325

info@molmed.com - [www.molmed.com](http://www.molmed.com)

Share capital €27,070,992.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

*For further information:*

**Marina Del Bue**

**General Manager Business & Administration**

MolMed S.p.A.

phone: +39 02 21277.371

fax: +39 02 21277.325

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**DISCLAIMER**

*This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.*